JP2013522238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522238A5 JP2013522238A5 JP2012557294A JP2012557294A JP2013522238A5 JP 2013522238 A5 JP2013522238 A5 JP 2013522238A5 JP 2012557294 A JP2012557294 A JP 2012557294A JP 2012557294 A JP2012557294 A JP 2012557294A JP 2013522238 A5 JP2013522238 A5 JP 2013522238A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- imidazo
- alkyl
- amine
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- (4- (tert-butyl) benzamido) -2-methylphenyl Chemical group 0.000 claims description 118
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 150000005829 chemical entities Chemical class 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 20
- 125000000335 thiazolyl group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- CJWSQMSEHQXXCY-UHFFFAOYSA-N 1-[2-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-5-yl]ethanone Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C(=O)C)=C1 CJWSQMSEHQXXCY-UHFFFAOYSA-N 0.000 claims description 2
- AAHVXELFAIWJBK-UHFFFAOYSA-N 1-[4-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 AAHVXELFAIWJBK-UHFFFAOYSA-N 0.000 claims description 2
- HHZJQTQNJPCNPC-UHFFFAOYSA-N 1-[4-[6-[[6-[3-(2-hydroxyethyl)-1h-indol-6-yl]imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=CN2C1=NC=C2 HHZJQTQNJPCNPC-UHFFFAOYSA-N 0.000 claims description 2
- AMKMRSDGPQZQLS-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]-3-methylazetidin-3-ol Chemical compound C1C(C)(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 AMKMRSDGPQZQLS-UHFFFAOYSA-N 0.000 claims description 2
- UYCXAUWDQCPVMY-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]-4-methylpiperidin-4-ol Chemical compound C1CC(C)(O)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 UYCXAUWDQCPVMY-UHFFFAOYSA-N 0.000 claims description 2
- MODZHSLQBONCHV-UHFFFAOYSA-N 1-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]azetidin-3-ol Chemical compound C1C(O)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 MODZHSLQBONCHV-UHFFFAOYSA-N 0.000 claims description 2
- IVHDGESMIPKUEO-UHFFFAOYSA-N 1-methyl-6-[5-methyl-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-3h-indol-2-one Chemical compound C1=C2N(C)C(=O)CC2=CC=C1C(=C(N1C=CN=C11)C)C=C1NC(N=C1)=CC=C1N1CCOCC1 IVHDGESMIPKUEO-UHFFFAOYSA-N 0.000 claims description 2
- VYICWLIDANWXNE-UHFFFAOYSA-N 2-[1-methyl-6-[5-methyl-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]indol-3-yl]ethanol Chemical compound C12=NC=CN2C(C)=C(C=2C=C3N(C)C=C(CCO)C3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VYICWLIDANWXNE-UHFFFAOYSA-N 0.000 claims description 2
- COXUVLHFSMGTNO-UHFFFAOYSA-N 2-[4-[[6-[3-(2-hydroxyethyl)-1h-indol-6-yl]imidazo[1,2-a]pyridin-8-yl]amino]phenyl]-2-methylpropan-1-ol Chemical compound C1=CC(C(C)(CO)C)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=CN2C1=NC=C2 COXUVLHFSMGTNO-UHFFFAOYSA-N 0.000 claims description 2
- QWHKXQBDXJJCHD-UHFFFAOYSA-N 2-[5-methyl-3-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyrazol-1-yl]ethanol Chemical compound OCCN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 QWHKXQBDXJJCHD-UHFFFAOYSA-N 0.000 claims description 2
- LUWFEEPUDGWECA-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1-methylindol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3N(C)C=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 LUWFEEPUDGWECA-UHFFFAOYSA-N 0.000 claims description 2
- WCSIPHYOIZRNNZ-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 WCSIPHYOIZRNNZ-UHFFFAOYSA-N 0.000 claims description 2
- CPYZUOJAUGIHIA-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1-methylindol-3-yl]ethanol Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3N(C)C=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 CPYZUOJAUGIHIA-UHFFFAOYSA-N 0.000 claims description 2
- OEZWQIKWWVKAJI-UHFFFAOYSA-N 2-[6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(Cl)N2C1=NC=C2 OEZWQIKWWVKAJI-UHFFFAOYSA-N 0.000 claims description 2
- UJLCAUDXTUPBJP-UHFFFAOYSA-N 2-[6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1=C2COCCN2N=C1NC1=CC(C=2C=C3NC=C(C3=CC=2)CCO)=CN2C=CN=C21 UJLCAUDXTUPBJP-UHFFFAOYSA-N 0.000 claims description 2
- XMRNHTWGJJNSMS-UHFFFAOYSA-N 2-[6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C=1C=C2C(CCO)=CNC2=CC=1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 XMRNHTWGJJNSMS-UHFFFAOYSA-N 0.000 claims description 2
- QSKNZFLYYGWRJV-UHFFFAOYSA-N 2-[6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]ethanol Chemical compound C1CC2C(CCO)NNC2CC1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 QSKNZFLYYGWRJV-UHFFFAOYSA-N 0.000 claims description 2
- VMJQTHKIUMLGNI-UHFFFAOYSA-N 2-[6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-1h-indol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(CCO)C3=CC=2)=C(C)N2C1=NC=C2 VMJQTHKIUMLGNI-UHFFFAOYSA-N 0.000 claims description 2
- OHRHYLMKOWOKNP-UHFFFAOYSA-N 2-[6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]ethanol Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C2CC3NNC(CCO)C3CC2)=CN2C1=NC=C2 OHRHYLMKOWOKNP-UHFFFAOYSA-N 0.000 claims description 2
- XIQBMHMYQXKVNB-UHFFFAOYSA-N 2-[ethyl-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]amino]ethanol Chemical compound N1=CC(N(CCO)CC)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 XIQBMHMYQXKVNB-UHFFFAOYSA-N 0.000 claims description 2
- XLWBHWLYRXBZRX-UHFFFAOYSA-N 2-hydroxy-1-[4-[6-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)CO)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 XLWBHWLYRXBZRX-UHFFFAOYSA-N 0.000 claims description 2
- GVZHUWSLJZJBOW-UHFFFAOYSA-N 2-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-n-(2-methoxyethyl)-5-n-methylpyridine-2,5-diamine Chemical compound N1=CC(N(C)CCOC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 GVZHUWSLJZJBOW-UHFFFAOYSA-N 0.000 claims description 2
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- ARLTZSGJPGABLS-UHFFFAOYSA-N 3-(2-hydroxyethyl)-6-[8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-benzimidazol-2-one Chemical compound C1=C2NC(=O)N(CCO)C2=CC=C1C(=CN1C=CN=C11)C=C1NC(N=C1)=CC=C1N1CCOCC1 ARLTZSGJPGABLS-UHFFFAOYSA-N 0.000 claims description 2
- TTXXVRQVMWILOX-UHFFFAOYSA-N 5-chloro-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(Cl)N2C1=NC=C2 TTXXVRQVMWILOX-UHFFFAOYSA-N 0.000 claims description 2
- JCGQOBWKAYVSHM-UHFFFAOYSA-N 5-chloro-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(Cl)N2C1=NC=C2 JCGQOBWKAYVSHM-UHFFFAOYSA-N 0.000 claims description 2
- NGNYRZRWQFOUFK-UHFFFAOYSA-N 5-ethyl-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(CC)N2C1=NC=C2 NGNYRZRWQFOUFK-UHFFFAOYSA-N 0.000 claims description 2
- HYULMKQXSAMIIE-UHFFFAOYSA-N 5-ethyl-n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(CC)N2C1=NC=C2 HYULMKQXSAMIIE-UHFFFAOYSA-N 0.000 claims description 2
- SMDZKFNTPDKVCD-UHFFFAOYSA-N 5-methyl-n-(5-morpholin-4-ylpyridin-2-yl)-6-(1h-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC=CN2C(C)=C(C=2C=C3C=CNC3=NC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 SMDZKFNTPDKVCD-UHFFFAOYSA-N 0.000 claims description 2
- VVVAHIMKXLXSAZ-UHFFFAOYSA-N 5-methyl-n-[6-(1h-pyrazolo[4,3-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-amine Chemical compound N1=C2C=NNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C)=C1 VVVAHIMKXLXSAZ-UHFFFAOYSA-N 0.000 claims description 2
- XGIBBFYEAXESGG-UHFFFAOYSA-N 5-methylsulfonyl-n-[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-amine Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)S(=O)(=O)C)=C1 XGIBBFYEAXESGG-UHFFFAOYSA-N 0.000 claims description 2
- HFLJFLGBUYZUQI-UHFFFAOYSA-N 6-(1,3-benzothiazol-5-yl)-n-(5,6-dimethoxypyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3N=CSC3=CC=2)=CN2C1=NC=C2 HFLJFLGBUYZUQI-UHFFFAOYSA-N 0.000 claims description 2
- VNVXBPDUZLOFDL-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxylic acid Chemical compound C12=NC=CN2C(C(=O)O)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VNVXBPDUZLOFDL-UHFFFAOYSA-N 0.000 claims description 2
- MMVVVHCESUZDJQ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(1-methylpyrazol-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 MMVVVHCESUZDJQ-UHFFFAOYSA-N 0.000 claims description 2
- RXLYIOCBKNBFKY-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(2-methoxypyrimidin-4-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound COC1=NC=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 RXLYIOCBKNBFKY-UHFFFAOYSA-N 0.000 claims description 2
- ASOHWEMFUOHJIO-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1COCCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 ASOHWEMFUOHJIO-UHFFFAOYSA-N 0.000 claims description 2
- SMDZVMZCRFMZLC-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(6-morpholin-4-ylpyridazin-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1COCCN1C(N=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SMDZVMZCRFMZLC-UHFFFAOYSA-N 0.000 claims description 2
- ZWZYOUWAHJEIEO-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-pyrimidin-4-ylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C=2C=C3NN=CC3=CC=2)=CN2C=CN=C2C=1NC1=CC=NC=N1 ZWZYOUWAHJEIEO-UHFFFAOYSA-N 0.000 claims description 2
- OPBMELYINMFWHW-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-chloro-N-[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]imidazo[1,2-a]pyridin-8-amine Chemical compound CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=CC(=C(N4C3=NC=C4)Cl)C5CCC6CNNC6C5 OPBMELYINMFWHW-UHFFFAOYSA-N 0.000 claims description 2
- AVVSZNQPPXNDTD-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-fluoro-N-[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]imidazo[1,2-a]pyridin-8-amine Chemical compound CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=CC(=C(N4C3=NC=C4)F)C5CCC6CNNC6C5 AVVSZNQPPXNDTD-UHFFFAOYSA-N 0.000 claims description 2
- ZUALLIRHZKQFCS-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-methyl-N-(5-morpholin-4-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CC1=C(C=C(C2=NC=CN12)NC3=NC=C(C=C3)N4CCOCC4)C5CCC6CNNC6C5 ZUALLIRHZKQFCS-UHFFFAOYSA-N 0.000 claims description 2
- POQYKNCZHZAFJV-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxamide Chemical compound C1CC2CNNC2CC1C3=C(N4C=CN=C4C(=C3)NC5=NC=C(C=C5)N6CCOCC6)C(=O)N POQYKNCZHZAFJV-UHFFFAOYSA-N 0.000 claims description 2
- WKMHWRRKVGSIQB-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(1,5-dimethylpyrazol-3-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NCCOC3=CC=2)=N1 WKMHWRRKVGSIQB-UHFFFAOYSA-N 0.000 claims description 2
- TVEGHVLNCAEJCT-UHFFFAOYSA-N 6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-n-(5,6-dimethoxypyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NCCOC3=CC=2)=CN2C1=NC=C2 TVEGHVLNCAEJCT-UHFFFAOYSA-N 0.000 claims description 2
- GVROMDVQUCKWGE-UHFFFAOYSA-N 6-[5-chloro-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(Cl)N2C1=NC=C2 GVROMDVQUCKWGE-UHFFFAOYSA-N 0.000 claims description 2
- QWTXOMHDNPKELH-UHFFFAOYSA-N 6-[5-chloro-8-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(Cl)N2C1=NC=C2 QWTXOMHDNPKELH-UHFFFAOYSA-N 0.000 claims description 2
- UNYZBRTVGVYOPI-UHFFFAOYSA-N 6-[5-ethyl-8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(CC)N2C1=NC=C2 UNYZBRTVGVYOPI-UHFFFAOYSA-N 0.000 claims description 2
- VUUURTUOFFIMSH-UHFFFAOYSA-N 6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-5-methylimidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 VUUURTUOFFIMSH-UHFFFAOYSA-N 0.000 claims description 2
- KUGHIXMRCSFERL-UHFFFAOYSA-N 6-[8-(6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2COCCN2N=C1NC1=CC(C2=CC=C3CC(NC3=C2)=O)=CN2C=CN=C21 KUGHIXMRCSFERL-UHFFFAOYSA-N 0.000 claims description 2
- AIZDDANRTXKWHE-UHFFFAOYSA-N 6-[8-[(1-ethylpyrazol-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound CCN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC(=O)COC3=CC=2)=N1 AIZDDANRTXKWHE-UHFFFAOYSA-N 0.000 claims description 2
- WDFOWXGTQYELBY-UHFFFAOYSA-N 6-[8-[(1-ethylpyrazol-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]quinazolin-2-amine Chemical compound CCN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3C=NC(N)=NC3=CC=2)=N1 WDFOWXGTQYELBY-UHFFFAOYSA-N 0.000 claims description 2
- AWKDVPHOKZABMA-UHFFFAOYSA-N 6-[8-[(5,6-dimethoxypyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-indazol-3-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=C(N)C3=CC=2)=CN2C1=NC=C2 AWKDVPHOKZABMA-UHFFFAOYSA-N 0.000 claims description 2
- HHKKVEQGIUFVDE-UHFFFAOYSA-N 6-[8-[(5-acetyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)C(=O)C)=C1 HHKKVEQGIUFVDE-UHFFFAOYSA-N 0.000 claims description 2
- BGWCPJXCPBYEGZ-UHFFFAOYSA-N 6-[8-[(5-methylsulfonyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2CC(=O)NC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCN(CC3=C2)S(=O)(=O)C)=C1 BGWCPJXCPBYEGZ-UHFFFAOYSA-N 0.000 claims description 2
- QZYWXLJTMHJVDD-UHFFFAOYSA-N 6-[8-[(6-morpholin-4-ylpyridazin-3-yl)amino]imidazo[1,2-a]pyridin-6-yl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1C(=CN1C=CN=C11)C=C1NC(N=N1)=CC=C1N1CCOCC1 QZYWXLJTMHJVDD-UHFFFAOYSA-N 0.000 claims description 2
- ALPRTTKLDJFBBW-UHFFFAOYSA-N 6-[8-[[1-(2-hydroxyethyl)-5-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound OCCN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC(=O)CC3=CC=2)=N1 ALPRTTKLDJFBBW-UHFFFAOYSA-N 0.000 claims description 2
- ZURICCOPZVTCKC-UHFFFAOYSA-N 6-[8-[[5-(1-hydroxy-2-methylpropan-2-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound N1=CC(C(C)(CO)C)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ZURICCOPZVTCKC-UHFFFAOYSA-N 0.000 claims description 2
- MUWCGKRRJVQKKE-UHFFFAOYSA-N 6-[8-[[5-(2-hydroxypropan-2-yl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-3-methyl-1h-benzimidazol-2-one Chemical compound C1=C(C(C)(C)O)N(C)N=C1NC1=CC(C=2C=C3NC(=O)N(C)C3=CC=2)=CN2C1=NC=C2 MUWCGKRRJVQKKE-UHFFFAOYSA-N 0.000 claims description 2
- ITTZAVWEURMZDA-UHFFFAOYSA-N 6-[8-[[5-(4-acetylpiperazin-1-yl)pyridin-2-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ITTZAVWEURMZDA-UHFFFAOYSA-N 0.000 claims description 2
- BNBHTSNPZVCWIT-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=C(C)N2C1=NC=C2 BNBHTSNPZVCWIT-UHFFFAOYSA-N 0.000 claims description 2
- VZYWHPBXQSDYJO-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-3-(2-methoxyethyl)-1h-benzimidazol-2-one Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(=O)N(CCOC)C3=CC=2)=C(C)N2C1=NC=C2 VZYWHPBXQSDYJO-UHFFFAOYSA-N 0.000 claims description 2
- CYNCIMVWMPLNDR-UHFFFAOYSA-N 6-[8-[[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino]-5-methylimidazo[1,2-a]pyridin-6-yl]-n-methyl-1h-indole-3-carboxamide Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=C(C3=CC=2)C(=O)NC)=C(C)N2C1=NC=C2 CYNCIMVWMPLNDR-UHFFFAOYSA-N 0.000 claims description 2
- ZZHTYBPWEZHTGD-UHFFFAOYSA-N 6-[8-[[5-(hydroxymethyl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(CO)N(C)N=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 ZZHTYBPWEZHTGD-UHFFFAOYSA-N 0.000 claims description 2
- PNUYPAFIVQXTMN-UHFFFAOYSA-N 6-n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]pyridine-2,6-diamine Chemical compound NC1=CC=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 PNUYPAFIVQXTMN-UHFFFAOYSA-N 0.000 claims description 2
- BRLWIFKLTDXPIT-UHFFFAOYSA-N 6-phenyl-n-pyridin-2-ylimidazo[1,2-a]pyridin-8-amine Chemical compound C=1C(C=2C=CC=CC=2)=CN2C=CN=C2C=1NC1=CC=CC=N1 BRLWIFKLTDXPIT-UHFFFAOYSA-N 0.000 claims description 2
- XPKXLBASWYFXNT-UHFFFAOYSA-N 7-[8-[(5,6-dimethoxypyridin-2-yl)amino]imidazo[1,2-a]pyridin-6-yl]-1h-quinoxalin-2-one Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3N=C(O)C=NC3=CC=2)=CN2C1=NC=C2 XPKXLBASWYFXNT-UHFFFAOYSA-N 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- LISFXZADUDULQH-UHFFFAOYSA-N C1(CC1)C1=CC(=NN1)NC=1C=2N(C=C(C=1)N1C(CC3=CC=CC=C13)=O)C=CN=2 Chemical compound C1(CC1)C1=CC(=NN1)NC=1C=2N(C=C(C=1)N1C(CC3=CC=CC=C13)=O)C=CN=2 LISFXZADUDULQH-UHFFFAOYSA-N 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- YMHITOQTVDEFGO-UHFFFAOYSA-N ClC1=C(C=C(C=2N1C=CN=2)NC1=NC=C(C=C1)N1CCN(CC1)C(C)C)N1C(N(C2=C1C=CC=C2)CCOC)=O Chemical compound ClC1=C(C=C(C=2N1C=CN=2)NC1=NC=C(C=C1)N1CCN(CC1)C(C)C)N1C(N(C2=C1C=CC=C2)CCOC)=O YMHITOQTVDEFGO-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- RVSYYOCTUBFIEA-HXUWFJFHSA-N [(2r)-4-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@@H](CO)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 RVSYYOCTUBFIEA-HXUWFJFHSA-N 0.000 claims description 2
- RVSYYOCTUBFIEA-FQEVSTJZSA-N [(2s)-4-[6-[[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1CO[C@H](CO)CN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 RVSYYOCTUBFIEA-FQEVSTJZSA-N 0.000 claims description 2
- YEYVGVKGXYMVCC-UHFFFAOYSA-N [2-methyl-5-[[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]amino]pyrazol-3-yl]methanol Chemical compound C1=C(CO)N(C)N=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 YEYVGVKGXYMVCC-UHFFFAOYSA-N 0.000 claims description 2
- VGNNTCALLGKSHX-UHFFFAOYSA-N [6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridin-5-yl]methanol Chemical compound C12=NC=CN2C(CO)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 VGNNTCALLGKSHX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- YVGHEDFSVFTXPY-UHFFFAOYSA-N n-(1,5-dimethylpyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=N1 YVGHEDFSVFTXPY-UHFFFAOYSA-N 0.000 claims description 2
- HAJVAUCPWNZZGX-UHFFFAOYSA-N n-(1,5-dimethylpyrazol-3-yl)-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 HAJVAUCPWNZZGX-UHFFFAOYSA-N 0.000 claims description 2
- XMUVBXMTSPNLPS-UHFFFAOYSA-N n-(1-ethyl-5-methylpyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(C)N(CC)N=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XMUVBXMTSPNLPS-UHFFFAOYSA-N 0.000 claims description 2
- QZKWYFPIFQWRHS-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 QZKWYFPIFQWRHS-UHFFFAOYSA-N 0.000 claims description 2
- SYSJQJZIAWYOMV-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SYSJQJZIAWYOMV-UHFFFAOYSA-N 0.000 claims description 2
- SRFSZFSWBWSJQH-UHFFFAOYSA-N n-(5,6-dimethoxypyridin-2-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound N1=C(OC)C(OC)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 SRFSZFSWBWSJQH-UHFFFAOYSA-N 0.000 claims description 2
- YXTJUKDGLBHAFK-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CC1C1=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=NN1 YXTJUKDGLBHAFK-UHFFFAOYSA-N 0.000 claims description 2
- RCLXJYDRYVESJQ-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-5-methyl-6-(2-methyl-1h-indol-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC(C)=CC3=CC=2)=C(C)N2C1=NC=C2 RCLXJYDRYVESJQ-UHFFFAOYSA-N 0.000 claims description 2
- UBPVTSSZDKOYFK-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indazol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NN=CC3=CC=2)=C(C)N2C1=NC=C2 UBPVTSSZDKOYFK-UHFFFAOYSA-N 0.000 claims description 2
- LGGCHDONPKSGDE-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-indol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=CC=2)=C(C)N2C1=NC=C2 LGGCHDONPKSGDE-UHFFFAOYSA-N 0.000 claims description 2
- CMHPYDOBMCOOAH-UHFFFAOYSA-N n-[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C1CN(CC)CCN1C(C=N1)=CC=C1NC1=CC(C=2C=C3NC=CC3=NC=2)=CN2C1=NC=C2 CMHPYDOBMCOOAH-UHFFFAOYSA-N 0.000 claims description 2
- FDSOXFJXLFBPIZ-UHFFFAOYSA-N n-[5-(methoxymethyl)-1-methylpyrazol-3-yl]-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CN1C(COC)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=NC=2)=N1 FDSOXFJXLFBPIZ-UHFFFAOYSA-N 0.000 claims description 2
- HZTAVSLVUIIUGL-UHFFFAOYSA-N n-[5-methyl-6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound N1=C2C=CNC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 HZTAVSLVUIIUGL-UHFFFAOYSA-N 0.000 claims description 2
- BPVLQNSUUBLGQQ-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)-5-methylimidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=NNC2=CC(C2=C(N3C=CN=C3C(NC3=NN4CCOCC4=C3)=C2)C)=C1 BPVLQNSUUBLGQQ-UHFFFAOYSA-N 0.000 claims description 2
- KAMBVFJWGKNGER-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-2-morpholin-4-yl-1,3-thiazol-4-amine Chemical compound C1COCCN1C1=NC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NN=CC3=CC=2)=CS1 KAMBVFJWGKNGER-UHFFFAOYSA-N 0.000 claims description 2
- ZZQOQJADXKUIPJ-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-methyl-1,2-oxazol-3-amine Chemical compound O1C(C)=CC(NC=2C3=NC=CN3C=C(C=2)C=2C=C3NC=CC3=CC=2)=N1 ZZQOQJADXKUIPJ-UHFFFAOYSA-N 0.000 claims description 2
- ONWRETPOJYEBFC-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-5-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-amine Chemical compound C1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NC=3CCN(CC=3S2)C)=C1 ONWRETPOJYEBFC-UHFFFAOYSA-N 0.000 claims description 2
- PYORNTJWSPQNLQ-UHFFFAOYSA-N n-[6-(1h-indol-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 PYORNTJWSPQNLQ-UHFFFAOYSA-N 0.000 claims description 2
- GVICIFRDMKTFNW-UHFFFAOYSA-N n-[6-(1h-pyrrolo[3,2-b]pyridin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound N1=C2C=CNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 GVICIFRDMKTFNW-UHFFFAOYSA-N 0.000 claims description 2
- GBBHSMOHDUTCDP-UHFFFAOYSA-N n-[6-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2COCCN2N=C1NC1=CC(C2=CC=C3OCCNC3=C2)=CN2C=CN=C21 GBBHSMOHDUTCDP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- ORNSLMJWQDGQFF-UHFFFAOYSA-N 1h-pyrido[2,3-b][1,4]oxazin-2-one Chemical compound C1=CC=C2NC(=O)COC2=N1 ORNSLMJWQDGQFF-UHFFFAOYSA-N 0.000 claims 1
- KSRWGJRHJUQFTH-UHFFFAOYSA-N 3-morpholin-4-ylpyridin-2-amine Chemical compound NC1=NC=CC=C1N1CCOCC1 KSRWGJRHJUQFTH-UHFFFAOYSA-N 0.000 claims 1
- SUUKTILQMGAGMW-UHFFFAOYSA-N 6-(2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-6-yl)-5-methyl-N-(5-piperazin-1-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound CC1=C(C=C(C2=NC=CN12)NC3=NC=C(C=C3)N4CCNCC4)C5CCC6CNNC6C5 SUUKTILQMGAGMW-UHFFFAOYSA-N 0.000 claims 1
- IDHJCPFMQJVVJT-UHFFFAOYSA-N 6-[8-[[5-(2-hydroxypropan-2-yl)-1-methylpyrazol-3-yl]amino]imidazo[1,2-a]pyridin-6-yl]-1,3-dihydroindol-2-one Chemical compound C1=C(C(C)(C)O)N(C)N=C1NC1=CC(C=2C=C3NC(=O)CC3=CC=2)=CN2C1=NC=C2 IDHJCPFMQJVVJT-UHFFFAOYSA-N 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- XRCXMMOXQGZKBD-UHFFFAOYSA-N n-[6-(1h-indazol-6-yl)imidazo[1,2-a]pyridin-8-yl]-6,7-dihydro-4h-pyrazolo[5,1-c][1,4]oxazin-2-amine Chemical compound C1=C2C=NNC2=CC(C=2C=C(C3=NC=CN3C=2)NC2=NN3CCOCC3=C2)=C1 XRCXMMOXQGZKBD-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 0 *c(cc1N*)c(*)[n]2c1ncc2 Chemical compound *c(cc1N*)c(*)[n]2c1ncc2 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- AGCIFROCRUWKFH-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-5-methyl-n-(5-piperazin-1-ylpyridin-2-yl)imidazo[1,2-a]pyridin-8-amine Chemical compound C12=NC=CN2C(C)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCNCC1 AGCIFROCRUWKFH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- NABGSOKMSDXZLC-UHFFFAOYSA-N methyl 6-(1h-indazol-6-yl)-8-[(5-morpholin-4-ylpyridin-2-yl)amino]imidazo[1,2-a]pyridine-5-carboxylate Chemical compound C12=NC=CN2C(C(=O)OC)=C(C=2C=C3NN=CC3=CC=2)C=C1NC(N=C1)=CC=C1N1CCOCC1 NABGSOKMSDXZLC-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31277110P | 2010-03-11 | 2010-03-11 | |
| US61/312,771 | 2010-03-11 | ||
| US31322310P | 2010-03-12 | 2010-03-12 | |
| US61/313,223 | 2010-03-12 | ||
| PCT/US2011/028194 WO2011112995A1 (en) | 2010-03-11 | 2011-03-11 | Imidazopyridines syk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094508A Division JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522238A JP2013522238A (ja) | 2013-06-13 |
| JP2013522238A5 true JP2013522238A5 (https=) | 2014-05-01 |
| JP5938352B2 JP5938352B2 (ja) | 2016-06-22 |
Family
ID=43828318
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557294A Active JP5938352B2 (ja) | 2010-03-11 | 2011-03-11 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2015094508A Expired - Fee Related JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2017136797A Withdrawn JP2017222685A (ja) | 2010-03-11 | 2017-07-13 | イミダゾピリジンｓｙｋ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094508A Expired - Fee Related JP6177828B2 (ja) | 2010-03-11 | 2015-05-05 | イミダゾピリジンｓｙｋ阻害剤 |
| JP2017136797A Withdrawn JP2017222685A (ja) | 2010-03-11 | 2017-07-13 | イミダゾピリジンｓｙｋ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9562056B2 (https=) |
| EP (1) | EP2545052B1 (https=) |
| JP (3) | JP5938352B2 (https=) |
| KR (1) | KR101717809B1 (https=) |
| CN (1) | CN103168039B (https=) |
| AU (3) | AU2011226689B2 (https=) |
| BR (1) | BR112012022943A2 (https=) |
| CA (1) | CA2792769C (https=) |
| ES (1) | ES2530449T3 (https=) |
| MX (1) | MX350010B (https=) |
| NZ (1) | NZ602362A (https=) |
| PT (1) | PT2545052E (https=) |
| WO (1) | WO2011112995A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102468A1 (en) | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| PL2716157T3 (pl) | 2008-12-08 | 2017-06-30 | Gilead Connecticut, Inc. | Imidazopirazynowe inhibitory Syk |
| PE20120121A1 (es) | 2008-12-08 | 2012-02-20 | Gilead Connecticut Inc | Derivados de imidazopirazina como inhibidores de syk |
| AU2011226689B2 (en) | 2010-03-11 | 2016-09-01 | Kronos Bio, Inc. | Imidazopyridines Syk inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| MX2014005285A (es) * | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos biciclicos de piperazina. |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| WO2013188856A1 (en) * | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN102898426B (zh) * | 2012-11-15 | 2015-04-22 | 江苏先声药业有限公司 | 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| SG11201600373YA (en) | 2013-07-31 | 2016-02-26 | Gilead Sciences Inc | Syk inhibitors |
| KR20160090903A (ko) | 2013-12-04 | 2016-08-01 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| SG11201610551TA (en) | 2014-07-14 | 2017-01-27 | Gilead Sciences Inc | Combinations for treating cancers |
| TW201617074A (zh) * | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2017097671A1 (de) * | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| AU2018286247B2 (en) * | 2017-06-14 | 2021-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Syk inhibitor and use method therefor |
| EP3672974A1 (en) | 2017-08-25 | 2020-07-01 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020140054A1 (en) | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112010879B (zh) * | 2020-09-15 | 2021-07-02 | 山西大学 | 一种Zn功能配合物及其制备方法和应用 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN113636973B (zh) * | 2021-09-07 | 2023-04-07 | 山东铂源药业股份有限公司 | 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
| JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| IL144202A0 (en) * | 1999-01-25 | 2002-05-23 | Biogen Inc | Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| KR20050008691A (ko) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법 |
| AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| MY133311A (en) * | 2002-09-19 | 2007-11-30 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase inhibitors |
| NZ538685A (en) | 2002-09-23 | 2008-02-29 | Schering Corp | Imidazopyrazines as cyclin dependent kinase inhibitors |
| NZ538686A (en) | 2002-09-23 | 2008-01-31 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004072080A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
| AR043002A1 (es) | 2003-02-18 | 2005-07-13 | Altana Pharma Ag | Imidazopirazinas 6-substituidos |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2005304473A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| US20070117804A1 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| TW200803863A (en) | 2005-11-10 | 2008-01-16 | Schering Corp | Method for inhibiting protein kinases |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| JP2010511019A (ja) * | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物 |
| JP5643105B2 (ja) * | 2007-12-14 | 2014-12-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体 |
| WO2009102468A1 (en) * | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| CN102131805A (zh) * | 2008-06-20 | 2011-07-20 | 百时美施贵宝公司 | 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物 |
| WO2010006947A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010038257A1 (ja) * | 2008-09-30 | 2010-04-08 | 株式会社アドバンテスト | プログラマブルデバイス、およびデータ書込方法 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| PL2716157T3 (pl) | 2008-12-08 | 2017-06-30 | Gilead Connecticut, Inc. | Imidazopirazynowe inhibitory Syk |
| PE20120121A1 (es) | 2008-12-08 | 2012-02-20 | Gilead Connecticut Inc | Derivados de imidazopirazina como inhibidores de syk |
| AU2011226689B2 (en) | 2010-03-11 | 2016-09-01 | Kronos Bio, Inc. | Imidazopyridines Syk inhibitors |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
| SG11201600373YA (en) | 2013-07-31 | 2016-02-26 | Gilead Sciences Inc | Syk inhibitors |
| KR20160090903A (ko) | 2013-12-04 | 2016-08-01 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| SG11201610551TA (en) | 2014-07-14 | 2017-01-27 | Gilead Sciences Inc | Combinations for treating cancers |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| CA2983611A1 (en) | 2015-04-21 | 2016-10-27 | Gilead Sciences, Inc. | Treatment of chronic graft versus host disease with syk inhibitors |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
-
2011
- 2011-03-11 AU AU2011226689A patent/AU2011226689B2/en active Active
- 2011-03-11 NZ NZ602362A patent/NZ602362A/en not_active IP Right Cessation
- 2011-03-11 MX MX2012010418A patent/MX350010B/es active IP Right Grant
- 2011-03-11 PT PT117096008T patent/PT2545052E/pt unknown
- 2011-03-11 JP JP2012557294A patent/JP5938352B2/ja active Active
- 2011-03-11 CA CA2792769A patent/CA2792769C/en active Active
- 2011-03-11 WO PCT/US2011/028194 patent/WO2011112995A1/en not_active Ceased
- 2011-03-11 US US13/806,094 patent/US9562056B2/en not_active Expired - Fee Related
- 2011-03-11 CN CN201180023252.0A patent/CN103168039B/zh not_active Expired - Fee Related
- 2011-03-11 KR KR1020127026472A patent/KR101717809B1/ko not_active Expired - Fee Related
- 2011-03-11 ES ES11709600T patent/ES2530449T3/es active Active
- 2011-03-11 BR BR112012022943A patent/BR112012022943A2/pt not_active Application Discontinuation
- 2011-03-11 EP EP11709600.8A patent/EP2545052B1/en active Active
-
2015
- 2015-05-05 JP JP2015094508A patent/JP6177828B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-23 AU AU2016219585A patent/AU2016219585B2/en active Active
- 2016-12-21 US US15/387,557 patent/US10092583B2/en active Active
-
2017
- 2017-07-13 JP JP2017136797A patent/JP2017222685A/ja not_active Withdrawn
-
2018
- 2018-05-08 AU AU2018203210A patent/AU2018203210A1/en not_active Abandoned
- 2018-09-06 US US16/124,113 patent/US10842803B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522238A5 (https=) | ||
| US11753407B2 (en) | Compounds for treating spinal muscular atrophy | |
| JP2012510998A5 (https=) | ||
| Cushing et al. | Discovery and in vivo evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl) quinolin-3-yl) ethyl)-9 H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease | |
| EP3875078A1 (en) | Compounds for the treatment of covid-19 | |
| KR20140128310A (ko) | 척수성 근위축증을 치료하기 위한 화합물 | |
| WO2012068096A2 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| JP2010507577A (ja) | トリアゾロピリダジンタンパク質キナーゼモジュレーター | |
| AU2011226689A1 (en) | Imidazopyridines Syk inhibitors | |
| JP2013518890A5 (https=) | ||
| MX2010014136A (es) | Nuevos derivados de fenilimidazola como inhibidores de la enzima pde10a. | |
| CN103459384A (zh) | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用和制造方法 | |
| WO2021142026A1 (en) | Shp2 inhibitor dosing and methods of treating cancer | |
| NZ575336A (en) | Bicyclic triazoles as protein kinase modulators | |
| AU2010249790A1 (en) | Benzoxazepines based P13K/mT0R inhibitors against proliferative diseases | |
| JP2023548657A (ja) | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 | |
| KR20160037198A (ko) | Syk 억제제 | |
| RU2012152548A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| JP2015534981A5 (https=) |